LPA1 is of great interest because therapeutic advances targeting it have been made through ongoing clinical trials to treat several diseases, including idiopathic pulmonary fibrosis (ClinicalTrials.gov ID: NCT01766817) and psoriasis (ClinicalTrials.gov ID: NCT02763969) [4]. Here, LPAR1 is linked to psoriasis.